Department of Surgery, Pritzker School of Medicine, University of Chicago, NorthShore University Health System, Evanston Hospital, Evanston, IL, USA.
Ann Surg Oncol. 2013 Oct;20(10):3223-32. doi: 10.1245/s10434-013-3154-8. Epub 2013 Aug 22.
Previous studies have demonstrated an increase in the utilization of accelerated partial-breast irradiation via brachytherapy (APBI-b), but larger, more contemporary studies examining overall APBI use are lacking.
A total of 575,438 nonneoadjuvant American Joint Committee on Cancer stage 0 to II breast conservation patients were selected from the National Cancer Data Base from 2003 to 2010 who underwent either whole-breast irradiation or APBI.
Overall, 59,396 patients (10.3 %) underwent APBI. The use of APBI for the entire cohort increased from 3.4 % in 2003 to 12.8 % (p < 0.001) in 2008 and then decreased to 12.4 % in 2010. Three-dimensional conformal radiation increased from 0.8 to 2.2 %, intensity-modulated radiotherapy increased from 0.7 to 1.3 %, and brachytherapy (APBI-b) increased from 2.0 to 8.9 %. The most significant factors associated with APBI use were patient age and facility location. Patients 80-89 years old were 3.8 times more likely to undergo APBI compared to patients 30-39 years old (odds ratio [OR] 3.77, 95 % confidence interval [CI] 3.45-4.10, p < 0.001). Patients living in the West census region were 2.0 times more likely to undergo APBI compared to patients living in the Northeast (OR 2.0, 95 % CI 1.93-2.15, p < 0.001). Using the American Society of Radiation Oncology (ASTRO) guidelines, among patients with noninvasive cancer who received APBI, 95.6 % were categorized as "cautionary" and 4.4 % as "unsuitable." Of the invasive patients, 43.8 % were categorized as "suitable," 47.0 % as "cautionary," and 9.2 % as "unsuitable."
The utilization of APBI has stabilized at approximately 12 % starting in 2008. The majority of APBI is delivered using APBI-b, with patient age being the most significant factor associated with APBI use.
先前的研究表明,通过近距离放疗(APBI-b)进行加速部分乳房照射的利用率有所增加,但缺乏更大规模、更具现代性的研究来检查整体 APBI 的使用情况。
从 2003 年至 2010 年,从国家癌症数据库中选择了 575438 名非新辅助性美国癌症联合委员会(AJCC)分期为 0 至 II 期的保乳患者,他们接受了全乳照射或 APBI。
总体而言,有 59396 名患者(10.3%)接受了 APBI。整个队列中 APBI 的使用率从 2003 年的 3.4%增加到 2008 年的 12.8%(p<0.001),然后在 2010 年降至 12.4%。三维适形放疗从 0.8%增加到 2.2%,调强放疗从 0.7%增加到 1.3%,而近距离放疗(APBI-b)从 2.0%增加到 8.9%。与 APBI 使用相关的最重要因素是患者年龄和医疗机构位置。80-89 岁的患者接受 APBI 的可能性是 30-39 岁患者的 3.8 倍(优势比[OR]3.77,95%置信区间[CI]3.45-4.10,p<0.001)。居住在西部普查区的患者接受 APBI 的可能性是居住在东北部的患者的 2.0 倍(OR 2.0,95%CI 1.93-2.15,p<0.001)。根据美国放射肿瘤学会(ASTRO)指南,在接受 APBI 的非浸润性癌症患者中,95.6%被归类为“谨慎”,4.4%被归类为“不合适”。在浸润性患者中,43.8%被归类为“合适”,47.0%被归类为“谨慎”,9.2%被归类为“不合适”。
从 2008 年开始,APBI 的使用率稳定在 12%左右。大多数 APBI 使用 APBI-b 进行,患者年龄是与 APBI 使用相关的最重要因素。